Treatment methods using adenovirus
AssigneeVascular Biogenics Ltd.
InventorsEyal Breitbart, Andrea Leubitz, Erez Feige, Richard Penson
Life of this patent
Estimating the term…
Abstract
The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.
Claims21
-107. (canceled)
A promoter comprising the sequence set forth in nucleotides 1 to 987 of SEQ ID NO:
- 18.
An isolated adenovirus having European Collection of Cell Cultures (ECACC) deposit designation 13021201.
A method of reducing or decreasing a size of a tumor or eliminating a tumor in a patient comprising administering to the patient an effective amount of a vector, which comprises a Fas-chimera gene operably linked to an endothelial cell-specific promoter, wherein a Fas-chimera gene product encoded by the vector reduces or decreases the size of the tumor or eliminates the tumor in the patient and wherein the tumor is associated with a female gynecological cancer or a metastasis thereof.
Dependencies are inferred from the claim text.